MARKET

CYBN

CYBN

Cybin Inc
AMEX
0.3550
-0.0054
-1.50%
Pre Market: 0.3530 -0.002 -0.56% 08:12 04/25 EDT
OPEN
0.3521
PREV CLOSE
0.3550
HIGH
0.3590
LOW
0.3372
VOLUME
2.87K
TURNOVER
0
52 WEEK HIGH
0.7380
52 WEEK LOW
0.2100
MARKET CAP
269.69M
P/E (TTM)
-1.6675
1D
5D
1M
3M
1Y
5Y
Cybin to Participate at the 27th Annual Milken Institute Global Conference
Cybin is a clinical-stage biopharmaceutical company developing next-generation psychedelic-based treatment options for mental health conditions. Doug Drysdale, Cybin’s Chief Executive Officer, will be speaking at the 27th Annual Milken Institute Global Conference. The Conference will take place May 5-8, 2024, at the Beverly Hilton in Los Angeles. The Company is currently developing a drug for the treatment of major depressive disorder.
Barchart · 6h ago
Weekly Report: what happened at CYBN last week (0415-0419)?
Weekly Report · 3d ago
Cybin Inc. Unveils Promising Psychedelic Research
TipRanks · 04/18 12:17
Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry
Cybin's research manuscript has been published in the Journal of Medicinal Chemistry. Cybin is a clinical-stage biopharmaceutical company committed to developing next-generation psychedelic-based treatment options for mental health and neurological disorders. The company's research led to the discovery of a potent and long-acting serotonin 5-HT2 receptor agonist.
Barchart · 04/18 06:30
NUMINUS WELLNESS INC: PHASE 3 TRIAL FOR CYB003 IS PLANNED TO COMMENCE ENROLLMENT MID-2024 AND FOCUS ON ITS SAFETY AND EFFICACY
Reuters · 04/17 11:00
Cybin Inc. Secures Patent, Progresses MDD Therapy
TipRanks · 04/16 12:09
CYBIN INC - TO COMMENCE ENROLLMENT FOR A MULTINATIONAL, MULTISITE PHASE 3 PROGRAM EVALUATING CYB003 IN MAJOR DEPRESSIVE DISORDER AROUND MID-YEAR 2024
Reuters · 04/16 11:30
Weekly Report: what happened at CYBN last week (0408-0412)?
Weekly Report · 04/15 11:39
More
About CYBN
Cybin Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company creates psychedelic-based therapeutics to address the unmet need for treatment options for people who suffer from mental health conditions. Its N,N-dimethyltryptamine (DMT) and dDMT programs creates a dataset of systematic research on these psychedelic molecules. The Company is developing CYB003, a proprietary deuterated psilocybin analog for the treatment of major depressive disorder and CYB004, a proprietary deuterated dDMT molecule for generalized anxiety disorder and has a research pipeline of investigational psychedelic-based compounds. CYB003 moves to Phase III and CYB004 moves to Phase II. It has an intellectual property portfolio in the psychedelic drug development sector with over 30 patents granted and 160 patents pending. The Company operates in Canada, the United States, the United Kingdom, the Netherlands and Ireland.

Webull offers Cybin Inc stock information, including AMEX: CYBN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYBN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CYBN stock methods without spending real money on the virtual paper trading platform.